Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40886 2500 Westchester Ave. Purchase, NY 10577 10577 (Address of Principal Executive Offices) (Zip Code) ...

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs - $30 Million Registered Direct Of ering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - Purchase, NY – November 6, 2025 – Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical- stage company devel ...

Core Insights - Cognition Therapeutics, Inc. has completed a $30 million registered direct offering to support the next stage of development for its drug zervimesine (CT1812) [2][8] - The company has aligned with the U.S. FDA on a registrational path for zervimesine in Alzheimer's disease, which is seen as a significant achievement [2][8] - An ongoing expanded access program for zervimesine in dementia with Lewy bodies is in place [8] Financial Highlights - As of September 30, 2025, the company reported cash, cash equivalents, and restricted cash equivalents of approximately $39.8 million, with total obligated grant funds remaining from the National Institute of Aging at $36.3 million [4] - Research and development expenses for Q3 2025 were $3.8 million, a decrease from $11.4 million in Q3 2024, attributed to the completion of clinical trials [5] - General and administrative expenses were $2.6 million for Q3 2025, down from $3.1 million in Q3 2024, primarily due to reduced stock-based compensation [6] - The net loss for Q3 2025 was $4.9 million, or $(0.06) per share, compared to a net loss of $9.9 million, or $(0.25) per share, for the same period in 2024 [6][11] Business Developments - The company has surpassed 75% enrollment in the Phase 2 'START' study of zervimesine in early Alzheimer's disease, which is being conducted in collaboration with the Alzheimer's Clinical Trials Consortium [8] - Clinical pharmacology and bioavailability studies are being executed to prepare zervimesine for the next stage of development across various indications [8] - The proposed registrational study design for Alzheimer's disease has been accepted for presentation at the Clinical Trials in Alzheimer's Disease (CTAD) Conference scheduled for December 1-4, 2025 [8]

Core Viewpoint - Cognition Therapeutics, Inc. (CGTX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating system is beneficial for investors as it focuses on objective earnings estimate revisions rather than subjective analyst ratings [3][7]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Rising earnings estimates and the upgrade for Cognition Therapeutics suggest an improvement in the company's underlying business, which could lead to higher stock prices [6]. Specifics on Cognition Therapeutics - For the fiscal year ending December 2025, Cognition Therapeutics is expected to earn -$0.40 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 1.2% over the past three months [9]. - The upgrade to Zacks Rank 2 places Cognition Therapeutics in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].

Industry Overview - Biotech and healthcare stocks are responding positively to clinical trial progress, regulatory developments, and economic indicators, particularly with the Federal Reserve's first rate cut of 2025, which is expected to improve funding conditions for capital-intensive sectors like biotechnology [1] Company Highlights - **Sonnet BioTherapeutics Holdings Inc. (SONN)**: Shares increased by 11.19% in after-hours trading, reaching $7.85 after a regular session close of $7.06. The stock has a 52-week range of $1.08 - $19.30. The company expanded clinical evaluation of its lead candidate, SON-1010, for ovarian cancer, reporting a strong safety profile and a partial response at the highest dose level [2][3] - **Akari Therapeutics Plc (AKTX)**: Shares surged 11.58% in after-hours trading to $0.8855 after closing at $0.7936. The stock has a 52-week range of $0.5710 - $3.8500. The increase follows a provisional patent filing for its antibody-drug conjugate platform aimed at cancer treatment, which is expected to enhance its intellectual property and support the development of first-in-class ADCs [4][5] - **Safety Shot Inc. (SHOT)**: Shares rose 9.75% in after-hours trading to $0.3333 after closing at $0.3037. The company announced a strategic refresh of its Board of Directors with three new members to strengthen its capabilities in digital assets and operations [6][7] - **Reviva Pharmaceuticals Holdings Inc. (RVPH)**: Shares climbed 10.09% in after-hours trading to $0.4451 after closing at $0.4043. The stock has a 52-week range of $0.3000 - $4.2800. The price movement follows a revised analyst rating maintaining a "Speculative Buy" while lowering the price target from $14.00 to $7.00. Reviva's lead candidate, brilaroxazine, is being developed for multiple neuropsychiatric and respiratory indications [8][9][10] - **Cognition Therapeutics Inc. (CGTX)**: Shares rose 7.48% in after-hours trading to $1.58 after closing down at $1.47. The company is focused on its lead candidate, Zervimesine, for Alzheimer's disease, and recently closed a $30 million offering to support its Phase 3 development [12][13]

Core Insights - Cognition Therapeutics, Inc. has announced that the Phase 2 'START' Study has reached 75% enrollment, targeting approximately 540 individuals with mild cognitive impairment (MCI) and early Alzheimer's disease [1][2] - The study is evaluating the efficacy of zervimesine (CT1812) over 18 months, in collaboration with the Alzheimer's Clinical Trials Consortium and funded by the National Institute of Aging [1][4] Study Details - The START Study (NCT05531656) aims to assess the efficacy and tolerability of once-daily oral zervimesine in individuals with MCI or early Alzheimer's disease who have elevated Aβ levels [3] - Participants are randomized to receive either zervimesine or placebo, with cognitive and executive function measured using validated tools such as the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and ADAS-Cog rating scales [3] Funding and Support - The START Study is supported by an $81 million grant from the National Institute of Aging [4] - The study is conducted in collaboration with the Alzheimer's Clinical Trials Consortium, which includes 35 leading academic sites specializing in Alzheimer's clinical trials [4] Previous Studies - The SHINE Study, a Phase 2 trial, enrolled 153 adults with mild-to-moderate Alzheimer's disease and met its primary endpoints of safety and tolerability [5][6] - The SHINE Study demonstrated that zervimesine slows cognitive deterioration in patients with lower levels of p-tau217 [2] Product Information - Zervimesine (CT1812) is an investigational oral medication aimed at treating CNS diseases like Alzheimer's and dementia with Lewy bodies [7] - The drug targets the toxic effects of protein buildup in the brain, potentially slowing disease progression and improving patient quality of life [7]

Core Viewpoint - Cognition Therapeutics, Inc. has successfully closed a registered direct offering of 14,700,000 shares of common stock at a price of $2.05 per share, raising approximately $30 million in gross proceeds to advance its drug zervimesine for neurodegenerative disorders [1][2]. Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6]. - The company has completed Phase 2 studies for its lead candidate, zervimesine (CT1812), targeting dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [6]. Product Information - Zervimesine (CT1812) is an investigational oral medication designed for the treatment of CNS diseases, specifically Alzheimer's disease and dementia with Lewy bodies [4]. - The drug aims to interrupt the toxic effects of Aβ and ɑ-synuclein proteins, which are associated with neurodegeneration, potentially slowing disease progression and improving patient quality of life [4]. Financial Details - The offering was facilitated by Titan Partners Group, which acted as the sole placement agent [2]. - The shares were offered under a shelf registration statement previously filed with the U.S. Securities and Exchange Commission, which was declared effective on January 3, 2023 [2].

Core Viewpoint - Cognition Therapeutics, Inc. has announced a registered direct offering of 14,700,000 shares of common stock, expected to generate approximately $30 million in gross proceeds to fund Phase 3 programs of zervimesine for neurodegenerative disorders and for general corporate purposes [1][2]. Group 1: Offering Details - The offering is made to two new fundamental institutional investors, including a prominent global investment manager [2]. - The closing of the offering is anticipated to occur on or about August 29, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the preparation of Phase 3 programs of zervimesine in neurodegenerative disorders, as well as for working capital and general corporate purposes [2]. Group 3: Company Background - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [5]. - The company has completed Phase 2 studies of zervimesine in conditions such as dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [5]. - The ongoing Phase 2 START study in early Alzheimer's disease is supported by $81 million in grant funding from the National Institute of Aging [5].

Core Points - Cognition Therapeutics, Inc. has regained compliance with Nasdaq's minimum share price requirement under Rule 5550(a)(2) [1][2] - The company achieved a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, with the requirement fulfilled on August 25, 2025 [2] - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for neurodegenerative disorders [3] Company Overview - Cognition Therapeutics is currently developing zervimesine (CT1812), targeting dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [3] - The Phase 2 START study in early Alzheimer's disease is ongoing, supported by $81 million in grants from the National Institute of Aging [3] - The mechanism of zervimesine involves interaction with the sigma-2 receptor, which is distinct from other treatment approaches for degenerative diseases [3]

Company Overview - Cognition Therapeutics (NASDAQ: CGTX) is advancing several clinical drug candidates, with a focus on zervimesine [CT1812] for treating patients [2]. Product Pipeline - The lead program under development is zervimesine [CT1812], which is being evaluated for its efficacy in treating specific patient populations [2]. Investment Insights - The Biotech Analysis Central service offers a comprehensive analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2].